The FDA has categorized this as a Class I recall, meaning the use of these devices could cause “serious injuries or death.”

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

ACC Vice President Cathleen Dalton Biga, MSN, RN, will serve as the group's next president. Cardiologist Christopher Kramer, MD, will be its next vice president. 

Overall, the recall includes 7,799 blood tests intended to help physicians identify early signs of a myocardial infarction. 

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 

The new 44-page document focuses on the detection, classification and risk assessment of congenital heart issues.

The minimally invasive system is made up of two pacemakers that send signals back and forth to one another. One pacemaker is placed on the patient's right ventricle, and the other is placed on the patient's right atrium. 

Researchers think this new technique could be beneficial for patients presenting with both severe symptomatic aortic stenosis and chronic kidney disease. 

The agency is looking to lift the longstanding NCD that restricts patients to one amyloid-detecting positron emission tomography exam in their lifetime.

The world’s present reckoning with a certain transformative technology ought to contain echoes of the past for CIOs and CTOs who were working their way up 10, 20 or even 30 years ago.